Transcriptome Li et al Science. 2011;333:53-58. N ew genomic studies show that the transfer of genetic information from DNA to RNA within humans is not very faithful. If true, frequent, or purposeful, then the implications for human health and disease are significant, but the burden of proof required is significant.
detected at a rate of 1.1ϫ10 -4 per exonic site (base) across human genes. Interestingly, they observed all 12 types of RNA-DNA differences possible with 4 bases across a variety of genes with the numbers of events (and rate) varying 10-fold across individuals and exonic sites. The vast majority of RDDs was detected in Ͻ10% of transcripts, but a random sample of 12 RDD sites could also be observed in other tissues (skin fibroblast and brain cortex) from the same individual (a different set than the 27). RDD was highly nonrandomly distributed: indeed the positions and rates of RDD varied significantly by chromosome even after correcting for gene density, by location within the transcript showing a marked 3' bias, and were clustered within the transcript. As further proof of the widespread nature of RDD, Li and colleagues 4 showed that RDD events do exist in EST (expressed sequence tags) databases and that proteomic analysis of B cells from the same human subjects showed amino acid substitutions that corresponded to specific RDD events observed in that individual. The proteomic analysis is not extensive enough yet to gauge the degree and extent of RDD that gets translated to peptide differences. Other groups have also identified RDD by computational analysis of genomic and transcriptomic data, 5, 6 whereas instances of RNA mutations not seen in DNA are known. 7 These results are intriguing and extraordinary, but its biological and medical impact is unknown. A fundamental question is whether RDD results from systematic, regulated, and predictable genetic processes or is random cellular noise varying across cells and time and having little to no effect on physiology, phenotype, or inheritance. Indeed, both of these "flavors" of RDD may be true. If, however, RDD is systematic and frequent, then a number of important biological and medical corollaries follow. First, transcript and protein diversity in individuals will result not only from alternative splicing but from RDD as well. Second, this diversity will create novel proteins that will usually be deleterious and rarely be advantageous. Third, RDD is a cellular "mutagen" and so will play a major role in the pathogenesis and/or modification of human disease. Fourth, RDD can result in completely unrelated phenotypes in close relatives since variation is no longer held to Mendelian inheritance. It would be an understatement that these findings do not raise skepticism that additional work needs to allay.
Although RDD has been experimentally demonstrated, 4 interpretation of these findings remains controversial. First, next-generation sequencing (NGS) technology is inaccurate, and one needs higher fidelity (coverage) data to rule out sequencing errors. Second, the mapping of the very short NGS reads is imperfect as many do not uniquely map to the human genome given their sequence is repeated. 8 Thus, RDD events could represent sequence differences between tran-scribed paralogs: if true, this would explain the EST and peptide data as well but not the 3' RDD bias. Third, the cellular RNA surveillance machinery should act on such variant transcripts. As is well known, transcripts with nonsense mutations are efficiently detected and removed to reduce transcriptional noise. 9 Perhaps at least some RDD events are disposed of in this way. Fourth, the extraordinarily high rate of RDD is surprising. There is no doubt that inheritance relies on DNA transmission, a process that has high fidelity since the genomic mutation rate is ϳ1-2ϫ10 -8 per base. 10, 11 Why would there be two mutually antagonistic conserved mechanisms: inheritance and RDD?
One explanation for RDD observations might be RNA editing, 12 a highly regulated molecular process in which the RNA sequence is chemically and enzymatically altered (see below). The classic example is that of Apolipoprotein B-100, a 4563-residue liver protein that transports cholesterol in the blood but whose intestinal transcript is edited by APOBEC1 at codon 2153 to lead to the 2152 residue intestinal protein Apolipoprotein B-48 that absorbs lipids. 13 This canonical editing produces two proteins with different functions in the liver and intestine from the same DNA sequence and is an efficient evolutionary tactic for tissue-specific expression. Whether RNA editing also occurs within a tissue is unknown and, if demonstrated, would be a major explanation for RDD.
RNA editing usually occurs as DNA3 RNA substitutions catalyzed by deaminases that recognize a specific target sequence of nucleotides: cytidine deaminases (APOBECs) convert C to U and adenosine deaminases (ADARs) convert A to I (inosine, which the ribosome translates as a G). Rarely, insertions or deletions mediated by guide RNA molecules can occur, but these alterations are not thought to be enzymatically created. Biologically, these are regulated "mutational" processes that create one purine or pyrimidine from another by chemical action. Although the enzymatic processes for DNA mutation and RNA editing are not the same, it is not surprising that in both cases transitional changes are overwhelmingly common. But curiously, transversion-type RDD events are more common than those in DNA mutations. Some of these RDD changes are likely from RNA polymerases that are far less accurate than DNA polymerases but the strong 3' bias is unexpected from such polymerase action. Do transversional RDDs arise from some novel enzymatic machinery that converts RNA purines to pyrimidines, and vice versa?
The evolutionary advantage of RDD is obscure: it may be a mechanism to increase cellular diversity, be a defense against viruses, or damage by retrotransposons. The most intriguing hypothesis, based on the 3' RDD bias, is that it may be a mechanism for preventing intramolecular basepairing and a protection against the RNA interference machinery. A second intriguing hypothesis is that RNA editing is intimately connected with RNA degradation itself. 14 However, these scenarios would be less compelling if RDD were not canonical (tissue specific).
RDD beyond obligate RNA editing, like any new biological phenomenon, can be an exciting development in biology and medicine or turn out to be an epiphenomenon or even result from genomic artifacts. Its importance should be judged by whether it turns out to be real, plausible, and purposeful. First, the observation of RDD in primary cells and its high rate exceeding that expected from sequencing, reverse transcription, and simple transcription errors suggest it maybe real. Nevertheless, additional studies are needed to rule out artifacts convincingly. Second, RDD plausibility needs to be rigorously established by demonstrating mechanisms for programmed transcription errors and transversional changes. A new basis for this activity needs to be identified. Third, a cellular purpose for RDD needs to be shown by demonstrating site conservation (between people and between tissues of the same person), evolutionary conservation, tissue, or developmental stage-specific regulation and that the observed rate accommodates proposed mechanisms of action. Many investigators will repeat the Li experiment in their favorite cell type and organism, and there is no doubt that the experiment should be replicated and improved. However, in the absence of a mechanistic understanding of how RDD occurs, widespread biological and medical interest in it will be difficult to sustain. After all, anything that revises a "central dogma" invites careful scrutiny.
